After Hours
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours.
Stocks Info
Xeris Biopharma Holdings Inc is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Biotechnology industry. The current market capitalization of Xeris Biopharma Holdings Inc is $903.63M. A total of 4.68 million shares were traded on the day, compared to an average of 2.35M shares.
In the most recent transaction, Hecht Beth sold 40,000 shares of XERS for 5.43 per share on Mar 20 ’25. After the transaction, the insider now owns 1,353,510 company shares. In a previous transaction on Mar 20 ’25, Hecht Beth bought 40,000 shares at 5.14 per share.
Among the insiders who bought shares, Schmid John P. acquired of 4,515 shares on Aug 12 ’24 at a per-share price of $2.25. This resulted in the Director holding 25,200 shares of XERS after the transaction. In another insider transaction, Schmid John P. bought 4,285 shares at $2.37 per share on Aug 09 ’24. Company shares held by the Director now total 20,685.
Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. In terms of 52-week highs and lows, XERS has a high of $5.97 and a low of $1.69.
As of this writing, XERS has an earnings estimate of -$0.04 per share for the current quarter. EPS was calculated based on a consensus of 1.0 estimates, with a high estimate of -$0.04 per share and a lower estimate of -$0.04.
Balance Sheet Annually/Quarterly
A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information. XERS’s latest balance sheet shows that the firm has $102.43M in Cash & Short Term Investments as of fiscal 2021. There were $88.07M in debt and $79.04M in liabilities at the time. Its Book Value Per Share was -$0.20, while its Total Shareholder’s Equity was $95.23M.
Analysts Opinion
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for XERS is Buy with a score of 4.67.
